Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ProMIS Neurosciences Inc. - Common Shares (NQ:PMN)

13.24 +0.44 (+3.44%)
Streaming Delayed Price Updated: 9:52 AM EDT, Jul 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ProMIS Neurosciences Inc. - Common Shares

< Previous 1 2 3 Next >
News headline image
ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences to Participate in Upcoming Conferences in June
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™)
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces Reverse Stock Split
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces Private Placement Financing
$3 million private financing plus an additional $9 million of proceeds due to exercise of warrants, for gross proceeds of approximately $12.0 million 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces Private Placement Financing
$2.4 million private financing plus an additional $6.8 million of proceeds due to exercise of warrants and $0.8 million from a registered offering for gross proceeds of $9.2 million 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease
FDA designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer’s Disease 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
Synergy (NASDAQ: SNYR) Strategic Partnership w/ McKesson (NYSE: MCK) Sends “FOCUSfactor” Exploding Across North America – More Stocks Inside
Via AB Newswire
News headline image
ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
Webcast of virtual fireside chat today, June 17th, at 7:00 a.m. ET 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces First Quarter 2025 Financial Results
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference
Multiple datasets support continued development of ProMIS’ antibody therapeutics and vaccines that selectively target toxic misfolded proteins to treat neurodegenerative diseases 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences to Participate in the 37th Annual Roth Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease
From ProMIS Neurosciences Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.